Page last updated: 2024-11-06

5,6-diamino-2,4-dihydroxypyrimidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,6-diamino-2,4-dihydroxypyrimidine, also known as 2,4-dihydroxy-5,6-diaminopyrimidine, is a key precursor in the biosynthesis of purine nucleotides. It is a fundamental building block in the synthesis of DNA and RNA. This compound is crucial for the replication and transcription processes, essential for life. Its synthesis is achieved through the conversion of glycine and formyltetrahydrofolate into 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), which is then converted to 5,6-diamino-2,4-dihydroxypyrimidine. Researchers extensively study this compound to understand the intricate mechanisms of nucleotide synthesis and explore potential therapeutic targets for diseases related to purine metabolism. '

5,6-diamino-2,4-dihydroxypyrimidine: structure given in first source; RN given refers to parent compound [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5,6-diaminouracil : An aminouracil in which the ring hydrogens at positions 5 and 6 on uracil have been replaced by amino groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID76726
CHEMBL ID34076
CHEBI ID46252
SCHEMBL ID33925
MeSH IDM0170642

Synonyms (48)

Synonym
5,6-diamino-2,4-dihydroxypyrimidine
5,6-diamino-pyrimidine-2,4-diol
2,4(1h,3h)-pyrimidinedione, 5,6-diamino-
unii-veu0fro9fl
ai3-52130
einecs 221-809-7
veu0fro9fl ,
4,5-diaminouracil
5,6-diaminopyrimidine-2,4(1h,3h)-dione
5,6-diaminouracil
DB03826
urn ,
CHEMBL34076
STL003068
5,6-diaminopyrimidine-2,4-diol
2,4(1h,3h)-pyrimidinedione, 5,6-diamino-, monohydrochloride
3240-72-0
4,5-diamino-2,6-dihydroxypyrimidine
5,6-diamino-1h-pyrimidine-2,4-dione
A5762
5,6-diamino-uracil
AKOS006229073
5,6-diamino-2,4-pyrimidinediol
FT-0619810
AKOS015854568
5,6-diamino-1,2,3,4-tetrahydropyrimidine-2,4-dione
STL477754
SCHEMBL33925
4,5-diamino-pyrimidin-2,6-dione
BBTNLADSUVOPPN-UHFFFAOYSA-N
DTXSID9062930
2,4-dihydroxy-5,6-diaminopyrimidin
SY024251
mfcd00016632
AC-26614
HMS3604N12
CS-W002107
J-018602
5,6-diaminopyrimidine-2,4-dione
CHEBI:46252
5,6-diaminopyrimidine-2,4-diol, 95%
Q27094704
AS-18288
AMY25282
BBL036794
SB57764
PD007206
13034-83-8
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
pyrimidoneA pyrimidine carrying one or more oxo substituents.
aminouracil
diamineAny polyamine that contains two amino groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID691396Drug degradation in DMSO assessed as bis-alloxazine and pyrimido[4,5-g]pteridine-2,4,7,9(1H,3H,6H,8H)-tetraone formation2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID23266Partition coefficient (logP)1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID691395Drug degradation in DMSO2012Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20
Compound instability in dimethyl sulphoxide, case studies with 5-aminopyrimidines and the implications for compound storage and screening.
AID220030Antioxidant activity in bovine heart mitochondria using iron(II) / dihydroxy fumaric acid (DHF)1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID230361Reducing activity to scavenge 10 uM 1, 1-diphenylpicrylhydrazyl (DPPH)1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
Long-chain-substituted uric acid and 5,6-diaminouracil derivatives as novel agents against free radical processes: synthesis and in vitro activity.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (11.11)18.7374
1990's1 (11.11)18.2507
2000's3 (33.33)29.6817
2010's3 (33.33)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.50 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]